RecruitingInterventional · Phase 1NCT02074839 ↗A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
RecruitingInterventional · Not applicableNCT02235857 ↗Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 SystemDarshana M DadhaniaPIInterventionDevice: LIPOSORBER® LA-15 SystemDatesMay 2015 – Sep 2027 (est.)SponsorKaneka Pharma America CorporationFocal Segmental Glomerulosclerosis
RecruitingInterventional · Phase 2NCT02974647 ↗Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaJia RuanPIInterventionDrug: RuxolitinibDatesNov 2016 – Nov 2027 (est.)SponsorMemorial Sloan Kettering Cancer CenterLymphoma
RecruitingInterventional · Phase 1/2NCT04150497 ↗Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)Gail J RobozPIInterventionBiological: UCART22 · Biological: CLLS52DatesOct 2019 – Jun 2026 (est.)SponsorCellectis, IncB-cell Acute Lymphoblastic Leukemia
RecruitingInterventional · Phase 1NCT05798897 ↗A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)Caitlin K GribbinPIInterventionDrug: MT-601DatesJan 2023 – Feb 2028 (est.)SponsorMarker Therapeutics, Inc.Non-Hodgkin Lymphoma, AdultNon-Hodgkin Lymphoma, RefractoryNon-Hodgkin Lymphoma, Relapsed+4 more
RecruitingInterventional · Phase 3NCT06615479 ↗A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple MyelomaMateo Mejia SaldarriagaPIInterventionDrug: BMS-986393 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Daratumumab · Drug: Pomalidomide · Drug: Dexamethasone · Drug: CarfilzomibDatesMar 2025 – Dec 2027 (est.)SponsorJuno Therapeutics, Inc.Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingInterventional · Phase 1/2NCT06634589 ↗A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell MalignanciesJohn AllanPIInterventionDrug: Tacabrutideg · Drug: Sonrotoclax · Drug: Zanubrutinib · Drug: Mosunetuzumab · Drug: Glofitamab · Drug: ObinutuzumabDatesNov 2024 – Dec 2028 (est.)SponsorBeiGene USAB-cell MalignancyRelapsed CancerRefractory Cancer+1 more
RecruitingInterventional · Phase 1NCT07082803 ↗An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination With Other Anti-Lymphoma Agents, in Patients With Relapsed or Refractory Non-Hodgkin LymphomasErin MulveyPIInterventionDrug: TLN-121 · Drug: zeprumetostat (TLN-254)DatesJun 2025 – Sep 2030 (est.)SponsorTreeline Biosciences INCLymphomaLymphoma, Non Hodgkin